Wen Xu, Zhang He-Da, Zhao Li, Yao Yu-Feng, Zhao Jian-Hua, Tang Jin-Hai
Department of General Surgery, Nanjing Medical University Affiliated Cancer Hospital, Cancer Institute of Jiangsu Province, China E-mail :
Asian Pac J Cancer Prev. 2015;16(3):1105-9. doi: 10.7314/apjcp.2015.16.3.1105.
Chemoresistance is the most common cause of chemotherapy failure during breast cancer (BCA) treatment. It is generally known that the mechanisms of chemoresistance in tumors involve multiple genes and multiple signaling pathways,; if appropriate drugs are used to regulate the mechanisms at the gene level, it should be possible to effectively reverse chemoresistance in BCA cells. It has been confirmed that chemoresistance in BCA cells could be reversed by ginsenoside Rh2 (G-Rh2). Preliminary studies of our group identified some drug- resistance specific miRNA. Accordingly, we proposed that G-Rh2 could mediate drug-resistance specific miRNA and corresponding target genes through the gene regulatory network; this could cut off the drug-resistance process in tumors and enhance treatment effects. G-Rh2 and breast cancer cells were used in our study. Through pharmaceutical interventions, we could explore how G-Rh2 could inhibit chemotherapy resistance in BCA, and analyze its impact on related miRNA and target genes. Finally, we will reveal the anti-resistance molecular mechanisms of G-Rh2 from a different angle in miRNA-mediated chemoresistance signals among cells.
化疗耐药是乳腺癌（BCA）治疗过程中化疗失败的最常见原因。众所周知，肿瘤中的化疗耐药机制涉及多个基因和多条信号通路；如果使用合适的药物在基因水平调节这些机制，应该有可能有效逆转BCA细胞中的化疗耐药性。已经证实人参皂苷Rh2（G-Rh2）可以逆转BCA细胞中的化疗耐药性。我们小组的初步研究鉴定了一些耐药特异性miRNA。因此，我们提出G-Rh2可以通过基因调控网络介导耐药特异性miRNA和相应的靶基因；这可以切断肿瘤中的耐药过程并增强治疗效果。我们的研究使用了G-Rh2和乳腺癌细胞。通过药物干预，我们可以探索G-Rh2如何抑制BCA中的化疗耐药性，并分析其对相关miRNA和靶基因的影响。最后，我们将从细胞间miRNA介导的化疗耐药信号的不同角度揭示G-Rh2的抗耐药分子机制。
